N3C is pleased to announce that ARIScience, an early user of N3C and also one of the finalists of the N3C-based COVID-19 AI pediatric challenge, has been awarded a research and development contract by the United States Biomedical Advanced Research Development Agency (BARDA) to discover candidate small molecules to counter respiratory depression by targeting two specific proteins. ARIScience continues to push its artificial intelligence combined with quantum chemistry-driven small molecule therapy discovery platform to target proteins that lie in disease pathways directly or allosterically across multiple disease conditions.
